|Other Names||Serine/threonine-protein kinase 17A, DAP kinase-related apoptosis-inducing protein kinase 1, STK17A, DRAK1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7220a was selected from the N-term region of human DRAK1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Acts as a positive regulator of apoptosis. Also acts as a regulator of cellular reactive oxygen species.|
|Tissue Location||Highly expressed in placenta. Lower levels in heart, lung, skeletal muscle, kidney and pancreas|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DRAK1 is a member of the DAP kinase-related apoptosis-inducing protein kinase family and encodes an autophosphorylated nuclear protein with a protein kinase domain. The protein has apoptosis-inducing activity.
Sanjo, H., et al., J. Biol. Chem. 273(44):29066-29071 (1998).
If you have any additional inquiries please email technical services at email@example.com.